Home / Business and Economy / Elekta Powers China Cancer Care with Local Innovation
Elekta Powers China Cancer Care with Local Innovation
5 Nov
Summary
- Elekta showcases advanced cancer treatment ecosystem at Shanghai's CIIE.
- Company marks 1,000th linear accelerator produced at Beijing factory.
- Elekta shifts focus to local innovation and global export from China.
Swedish medical technology company Elekta is currently showcasing its latest advancements in precision cancer treatment at the 9th China International Import Expo in Shanghai. The company is presenting a comprehensive ecosystem for adaptive radiotherapy and is emphasizing its expanding research and manufacturing capabilities within China.
Elekta is also releasing the "China MRgRT White Paper 2026" and has reached a milestone by producing its 1,000th high-energy medical linear accelerator at its Beijing factory. This participation aligns with China's national initiatives to bolster medical innovation and enhance healthcare access.
According to Gong Anming, president for China at Elekta, the company is transitioning from introducing global technologies to fostering local innovation, with China being a critical strategic market for its global operations. Elekta's Unity system has benefited over 15,000 patients across 17 Chinese medical institutions since its Asian debut.
The company's Beijing facility serves as a key production and innovation hub, while its Shanghai center is its largest global software development site. Elekta achieved full localization of its product portfolio in China in 2025, with locally manufactured equipment now exported worldwide.
Elekta's AI-powered AutoART technology significantly enhances radiotherapy efficiency. Foreign medical technology firms like Elekta are recognized for their role in advancing China's healthcare sector through investment and technological development, contributing to a more sophisticated medical ecosystem.
